Pfizer Inc. investors are closely watching the development of a mid-stage oral GLP-1 drug for type 2 diabetes and obesity given how lucrative the obesity market is expected to be. But if Pfizer does successfully develop danuglipron in late-stage clinical trials, the company would be entering a market dominated by experienced rivals Novo Nordisk A/S and Eli Lilly and Company.
Key Takeaways
- Pfizer updated investors on the development of an oral GLP-1 agonist for obesity
- The development of a once daily GLP-1 candidate was terminated in June
- Danuglipron is dosed twice daily
- Management assured investors
The three companies are all working to bring oral GLP-1 drugs to market for obesity, with Novo Nordisk squarely in the lead with the development of a high-dose version of semaglutide
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
